Comparison of Random Periareolar Fine Needle Aspirate versus Ductal Lavage for Risk Assessment and Prevention of Breast Cancer

Abigail Hoffman · Rod Pellenberg · Catherine Ibarra Drendall · Victoria Seewaldt

Published online: 22 June 2012
© The Author(s) 2012. This article is published with open access at Springerlink.com

Abstract Random periareolar fine needle aspiration (RPFNA) and ductal lavage (DL) are research techniques developed to (1) assess short-term breast cancer risk in asymptomatic women who are at increased risk for breast cancer and (2) track cytological response to risk reduction strategies. RPFNA and DL provide minimally invasive methods to repeatedly sample epithelial cells and research tools to investigate the biological origins of breast cancer in high-risk women. This review gives an overview of the strengths and limitations of both RPFNA and DL for risk assessment and breast cancer prevention in asymptomatic high-risk women.

Keywords Ductal lavage · DL · Random periareolar fine needle aspiration · RPFNA · Breast cancer risk · Breast cancer prevention · Biomarkers · Mammary atypia

Introduction

A woman’s breast cancer risk increases with a first-degree family history of breast cancer, a Gail risk score of 1.66 or greater, BRCA1/2 genetic mutation, or the presence of atypical hyperplasia. There is also evidence that cytological atypia in breast fluid or breast aspirate increases a woman’s risk of subsequently developing breast cancer. Random periareolar fine needle aspiration (RPFNA) and ductal lavage (DL) are minimally invasive research tools that are currently being utilized in a variety of clinical trials to test for the presence of cytological atypia in high-risk asymptomatic women and to track response to risk reduction strategies.

Breast cancer incidence has been shown to be reduced in high-risk cohorts by chemoprevention agents such as tamoxifen and through prophylactic surgery [1–4]. However, not all risk reduction strategies are effective in all women, and moreover, they may carry potential side effects. Furthermore, our current clinical trial design makes it difficult to prospectively identify individual women who are responding to a risk reduction intervention or a prevention agent. The length of time required for prospective validation of a predictive biomarker is not an efficient method for implementing safe and effective therapeutic treatments. Emerging evidence suggests that combined interventions such as weight loss, exercise, and a targeted prevention agent may be more effective than a single intervention alone. As a result, there is an increasing need to identify biomarkers that will accurately predict short-term breast cancer risk in individual women and rapidly assess response to complex risk reduction strategies.

Biomarkers that vary with risk and response to prevention interventions are referred to as surrogate endpoint biomarkers [5]. As has been outlined by Fabian et al. [6],
surrogate endpoint biomarkers should be (1) biologically and statistically significantly associated with cancer development, (2) present in a reasonable proportion of at-risk individuals, (3) obtainable by minimally invasive procedures, and (4) reversible with prevention interventions that have been validated to decrease cancer incidence. Many modalities have been suggested as potential surrogate endpoint biomarkers for breast cancer, including mammographic density, serum biomarkers, and breast tissue biomarkers [7–10]. Currently, there is no consensus as to the optimal surrogate endpoint biomarker.

Breast tissue biomarkers offer the advantage of directly testing for precancerous changes in the breast. Atypia and lobular carcinoma in situ (LCIS) are associated with increased breast cancer risk [11]. Moreover, breast cancer incidence in women with atypical hyperplasia or LCIS is substantially reduced after treatment with tamoxifen [1, 2]. However, the optimal method to repeatedly sample breast tissue remains controversial. Repeated random core needle biopsies for risk surveillance and/or for measurement of response to a prevention intervention can cause significant patient discomfort and are problematic because, unless the biopsy specimens are obtained from mammographically dense areas, the biopsy is likely to contain few terminal ductal–lobule units [12]. Nipple aspirates have shown some promise. However, approximately 40 % of nipple aspirates are acellular [13]. Here, we aim to review the strengths and limitations of two research techniques, RPFNA and DL, that have been developed to repeatedly sample mammary epithelial cells and to test surrogate biomarkers of response to prevention in individual high-risk women.

Random Periareolar Fine Needle Aspiration (RPFNA)

RPFNA is a research technique that was developed by Carol Fabian, M.D., at the University of Kansas in the mid-1980s to (1) assess short-term breast cancer risk in women at high risk for breast cancer and (2) track cytological response to risk reduction strategies [6, 14]. RPFNA is distinct from diagnostic FNA. Whereas diagnostic FNA is a standard clinical technique used to evaluate a clinically identifiable breast mass, breast RPFNA aims to provide a sampling of cells from the entire breast of asymptomatic women. Therefore, RPFNA has the advantage of being able to provide a “snap-shot” of the whole breast. The strengths of RPFNA are that (1) the technique can be performed successfully in a majority of high-risk women (72 %–85 % cell yield) and (2) the presence of cytological atypia in RPFNA has been shown to prospectively predict short-term breast cancer risk in high-risk women [15–17].

In 1986, the late Helene Smith proposed that breast cancer developed in a “high-risk field” or segment of the breast containing molecular changes that promote the development of a malignancy [18]. The existence of a “high-risk field” remains controversial; however, it is clear that when proliferative changes are present in the breast, these changes occur in a multifocal and multicentric pattern [19–21]. RPFNA has the ability to sample multifocal proliferative changes and to evaluate potential “field-effects.” This is particularly useful for short-term prevention trials because the aim of these studies is not to biopsy or treat a focal lesion but, rather, to induce antiproliferative or biomarker changes throughout an at-risk breast or within a “high-risk field.”

Performance of RPFNA

The breast is anesthetized with 5 cc of 1 % lidocaine, 2–5 cm from the areola (depending on the size and shape of the breast), at approximately three and nine o’clock. Nine aspirations are performed per breast, with four aspirations from the medial skin site and five from the lateral breast site. While aspirations are guided by the tactile identification of stromal/ductal tissue, there is no attempt to aspirate a specific location within the breast (Fig. 1). Aspirated cells contain a mixture of epithelial, stromal, adipose, and immune cells. These cells are pooled and placed in modified CytoLytTM with 1 % formalin for 24 h. Carol Fabian’s group pools cells from both breasts into a single sample [6], whereas, the Cancer and Leukemia Group B (CALGB) Prevention Group pools cells from the right and left breast separately, so as to obtain one sample per aspirated breast [22].

Masood Score Evaluation of RPFNA Cytology

RPFNA epithelial cytology is most frequently evaluated on thin layer cytologic preparation using the Masood Cytology Index score, a semiquantitative, numeric assessment scale that is weighted toward epithelial nuclear morphology. A minimum of one epithelial cell cluster with >10 epithelial cells is required for assessment, and the most abnormal cell cluster is scored [16, 17]. Epithelial cells are given a score of 1 to 4 points for each of the six morphological characteristics: cell
arrangement, pleomorphism, number of myoepithelial cells, anisonucleosis, nucleoli, and chromatin clumping. The sum of these points computes the Masood score: <10, nonproliferative (normal); 11–13, hyperplasia; 14–17, atypia; and >17, suspicious cytology [16, 17]. The numbers of epithelial cells are quantified and classified as <10 cells (insufficient), 10–100 cells, 101–500 cells, 501–1,000 cells, 1,001–5,000 cells, and >5,000 cells. The number of epithelial cells increases with the degree of cytological atypia; epithelial cell yield ranges from (1) $10^4$ to $5 \times 10^6$ (Masood 11–13), (2) $10^6$ to $5 \times 10^8$ (Masood 14–17), and (3) $10^7$ to $10^9$ (Masood >17). Accordingly, epithelial cytology from repeat samples possibly provides the ability to examine risk biomarkers and to prospectively predict the subsequent development of breast cancer.

Predictive Ability of RPFNA to Prospectively Identify Short Term Breast Cancer Risk

In 2000, Carol Fabian conducted a single institution study that demonstrated that cytological atypia in RPFNA independently predicted for an increase in breast cancer risk in high-risk women [6]. In this trial, 480 women at increased risk for breast cancer on the basis of (1) family history of breast cancer, (2) a prior diagnosis of breast cancer, or (3) precancerous biopsy prospectively underwent RPFNA. Investigators tested for the ability of cytological atypia in the initial RPFNA aspiration and Gail risk score to prospectively predict the subsequent development of breast cancer. At a 45 months follow-up, 20 women developed breast cancer. Of these, there were 7 DCIS and 13 invasive breast cancers. Multiple logistic regression and Cox proportional hazards analysis demonstrated that either the presence of cytological atypia in the initial RPFNA or a 10-year Gail projected an increased probability of developing breast cancer. The presence of cytological atypia in RPFNA predicted for a 5.6-fold increase in the subsequent development of breast cancer. This study supported the use of cytological atypia in RPFNA as a marker for high-risk benign lesions in high-risk women and supported the use of RPFNA in subsequent risk assessment and prevention studies [6].

Advantages and Limitations of RPFNA

RPFNA has the advantages of being inexpensive, performed in a clinic exam room, and repeatable, allowing for the serial assessment of predictive biomarkers. The majority of RPFNA aspirates in high-risk premenopausal and perimenopausal women are cellular [23, 24]. As was described above, the study of Fabian et al. prospectively validated the use of cytological atypia in RPFNA as a surrogate risk marker in high-risk women. However, the study of Fabian et al. has limitations, because it is single-institution study and cannot be generalized to average-risk women. No study has been performed to independently confirm the ability of cytological atypia in RPFNA to predict development of breast cancer.

While RPFNA has gained in acceptance, its use is limited by the absence of data with respect to reproducibility in the technique and interpretation in multiinstitutional studies. To address these potential limitations, the CALGB Prevention Group tested the reproducibility of RPFNA in a multiinstitutional cross-sectional study of high-risk women [22•]. In this study, Masood Cytology Index scores and two cell count measurements were compared from RPFNA samples of 63 individual women from five institutions (Duke University, Ohio State University, Roswell Park, University of Vermont, and Dana Farber Cancer Institute). All investigators were individually trained to do RPFNA by Carol Fabian at the University of Kansas. RPFNA was performed on the same breast, on the same day, by the same investigator, using separate needles for sequential aspirations. Masood Cytology Index score and epithelial cell count were assigned by a blinded, single dedicated cytopathologist (C.M.Z.). In this study, RPFNA was found to be highly reproducible with the overall Spearman correlation coefficients for Masood Cytology score and cell count of .8312 ($p<.0001$) and .7260 ($p<.0001$), respectively. Importantly, the reproducibility of duplicate RPFNA samples from the same breast was not affected by age, body mass index, 5-year Gail risk score, menopausal status, BRCA1/2 mutation, or the number of first-degree family members with breast and/or ovarian cancer [22•].

Studies performed by the CALGB Prevention Group provide evidence that RPFNA measurements are reproducible in a cooperative group setting and support the future use of RPFNA in multiinstitutional prevention trials. However, there were several limitations to this study. First, the number of subjects was small (63 women). Second, intraoperator variability of RPFNA was assessed, but the interoperator variability was not. The concordance between RPFNA measurements provided evidence that single operators in multiple institutions can produce similar results. But this study did not address whether different operators would have similar findings in the same woman. Despite the limitations of this study, these data provide important validation of the reproducibility of RPFNA in a multiinstitutional cross-sectional study that included cohorts that varied in demographic composition [22•].

Biomarker and Prevention Studies Utilizing RPFNA

Carol Fabian’s group pioneered the use of RPFNA-based biomarkers [14]. The first prevention study utilizing RPFNA-based biomarkers was a double-blind randomized Phase II chemoprevention trial [14] of alpha-difluoromethylornithine.
(DFMO) in 119 women at high risk for the development of breast cancer. Prior to entry, women were required to have RPFNA cytology that exhibited hyperplasia or hyperplasia with atypia, as well as a mammogram and clinical breast exam judged as not suspicious for breast cancer. Subjects were randomized to take 0.5 g/m² DFMO or placebo p.o. once per day for 6 months, followed by a repeat RPFNA. Of 119 subjects entered, 96 % completed the study and were evaluable for the main study end point [14]. The trial demonstrated no change in RPFNA cytology and RPFNA-based secondary end points of breast molecular marker changes (immunocytochemical [IC] expression of proliferating cell nuclear antigen, p53, and epidermal growth factor receptor) [14]. Since then, numerous studies have tested expression of IC and methylation biomarkers in RPFNA epithelial cytology [14, 19–21, 22*, 23–30]. The key limitation of all RPFNA-based biomarkers is the heterogeneous nature of the cell populations being tested for specific molecular markers. Recently, investigators have performed investigator-blinded proteomic profiling of RPFNA epithelial cytology, using the reverse phase proteomic microarray (RPPM) [31*, 32]. Up to 60 phosphoproteins can be tested in triplicate from 5,000 to 10,000 microdissected RPFNA epithelial cells. These studies provide the feasibility for tracking phosphoprotein network signaling in RPFNA cytology in response to risk reduction strategies, as well as having the potential to increase our understanding of the earliest events in mammary carcinogenesis in high-risk women. For example, the RPPM analysis of epithelial cells from RPFNA samples of nonobese and obese high-risk women has identified a potential crosstalk between the receptor tyrosine kinase/mammalian target of rapamycin signaling with interleukin-6/signal transducer and activator of transcription signaling in vimentin expression (unpublished results). Given the established associations between obesity and adipokines in breast cancer risk, future proteomic studies will employ serum and breast RPFNA samples to determine protein expression changes in the aforementioned signaling networks of high-risk women undergoing preventative interventions, such as diet and exercise. While this strategy appears promising, large-scale adoption of RPPM-RPFNA-based biomarkers will depend on robustness and reproducibility in investigator blinded, multiinstitutional trials.

Ductal Lavage (DL)

DL is an experimental technology that utilizes nipple fluid to identify high-risk and occult malignant lesions in breast epithelial cells. Initial data from a multicenter study by Dooley et al. [33] established the safety and tolerability of the procedure and increased cell yield for diagnostic evaluation, as compared with nipple aspirates. Five hundred seven high-risk women were enrolled, including 57 % with a history of contralateral breast cancer and 39 % with a 5-year Gail risk of >1.7 %. NAF production was possible in 83 % of these women, and 77 % of these women had DL performed, yielding adequate evaluable epithelial cells for cytologic diagnosis in 60 % (299/507) of the patients. The median number of epithelial cells from evaluable NAF specimens was 120 cells per breast, as compared with 13,500 epithelial cells per duct with DL. DL was 3.5 times more successful at producing cytologically evaluable fluid, as compared with NAF (73 % vs. 22 %, respectively; p <.001), and therefore, offered a more sensitive method of detecting cellular atypia [33]. Cytology findings for DL demonstrated inadequate cellular material for diagnosis in 22 %, benign in 54 %, mildly atypical in 17 %, and markedly atypical or malignant in 7 % of patients. The cytopathology results are intended for detection of epithelial atypia to improve the precision of breast cancer risk assessment, for detection of occult malignant lesions, and for potential serial observation in chemoprevention clinical trials.

Performance of Ductal Lavage

The procedure begins with breast massage and placement of a suction device to the nipple to identify fluid-yielding ducts and visualize non-fluid-yielding ducts, which are then cannulated with a microcatheter, infused with saline or physiologic solution, and then aspirated to collect cells from the lining of the milk duct (Fig. 2). The location of the lavaged duct is recorded on a grid to mark the position for future repeat lavage. The resultant fluid is then analyzed for cytology and categorized as insufficient cellular material for cytologic diagnosis, benign, mild atypia, severe atypia, or malignant.

Predictive Ability of Ductal Lavage to Prospectively Identify Short-Term Breast Cancer Risk

The potential for early detection of breast cancer by DL was examined in 2004 by Khan et al. [34] in 39 women with known breast cancer undergoing mastectomy. In this study, lavage was possible in 36 (82 %) of 44 breasts, and 31 (70 %) specimens had sufficient cellularity, excluding specimens that were acellular or contained fewer than 100 epithelial cells. A high-threshold positive test, defined as markedly atypical or malignant cytology, was found in only 13 % (5/38) of cancerous breasts, whereas a low-threshold positive test that additionally included mildly atypical cytology was present in 42 % (16/38) of cancerous breasts. Therefore, the sensitivity for cancer detection was 13 %–42 % when marked versus mild
atypia was included, which was attributed to cancer-containing ducts failing to yield fluid or having benign or mildly atypical cytology. These results challenge the previous hypothesis that the breast ducts yielding fluid on nipple aspiration are the ones most likely to contain malignant disease. Similar findings were shown in a study performed at Stanford [35] in which 38 women underwent the DL procedure with 30 successful attempts that resulted in 7/30 (23.3%) with atypical lavage cytology. Of the ducts that yielded atypia, five of seven were from ducts that were non-fluid-yielding on initial suction aspiration. In addition, only one of seven patients with atypia in DL fluid had a normal breast MRI and mammogram screening of the affected breast; however, six of seven patients with atypia had normal mammograms [35]. Maddux et al. determined that atypia was equally as likely to be found in both fluid-producing and dry ducts (19% vs. 15%) [36]. However, Wood et al. found that nipple aspiration fluid was more commonly expressed in cancerous, as compared with unaffected, breasts. Overall, sensitivity for detecting marked atypia or malignant cells in affected breasts was 17%, which is comparable to the results in other studies [37].

Advantages and Limitations of Ductal Lavage

DL is a nonsurgical breast epithelial sampling procedure that was developed to enhance the cellularity and reproducibility for detection of epithelial atypia and for serial observation in chemoprevention trials. DL offers the ability to label individual ducts for future recannulation in order to decrease sample variance in prevention trials, in addition to identifying the location of any abnormal cells found by cytopathology. However, the efficacy of DL for the serial monitoring of breast epithelium was tested for reproducibility in a study of 23 women, indicating that fewer than 50% of women producing atypical DL samples on the first attempt were found to have atypical samples on a repeat DL attempt [38]. The reliability of DL was also tested by Visvanathan et al. [39] and demonstrated a high rate of inadequate cellular material for diagnosis with fair cytologic reproducibility and low participant return rate. Reproducibility was further examined at Northwestern University in 2008, resulting in comparable low reproducibility of cell yield and cytologic findings after a baseline and 6-month repeat DL was performed in 65 high-risk women. Cytologic diagnosis was reproducible only in 43% of patients, concluding the limited value of DL for serial monitoring in chemoprevention trials [40]. Tolerability of DL has been reported as a possible limitation to its clinical use. The first multiinstitutional study of DL by Dooley et al. [33] reported the procedure to be well tolerated without any documented serious adverse events. Nonetheless, the study states that 51% reported DL as less comfortable than mammography, and 44% experienced breast pain. Another study reported that DL was not well tolerated, in part due to increased pain, as compared with mammography and NAF. There was also a low participant return rate for a repeat DL [39]. In 2009, the tolerability of DL was again examined closely among high-risk women and resulted in increased anticipated, in addition to increased experienced, discomfort versus mammogram, MRI, or NAF. Here, 25% of women refused to repeat DL [41].

Biomarker and Prevention Studies Utilizing Ductal Lavage

Optimal breast cancer predictive models are combining biologic and clinical markers to enhance the sensitivity of DL and identify characteristics of malignant changes within the breast. For example, DL was utilized for cancer detection in 2002 by King et al. [42] with 39 paired cases of surgically excised breast lesions and DL specimens collected prior to surgery. The study showed a sensitivity of 47% and a specificity of 79% in surgical specimens demonstrating abnormal cytology. Results were enhanced by the use of molecular markers consisting of

---

**Fig. 2** Ductal lavage. a Nipple fluid aspirator. The procedure begins with breast massage and placement of a suction device to the nipple to identify fluid-yielding ducts and visualize non-fluid-yielding ducts. b Single lumen duct lavage connected to inflow and outflow syringes. Saline is infused through the inflow syringe and then aspirated to collect cells from the lining of the milk duct.
Comparison of DL and RPFNA as tissue acquisition methods in early breast cancer prevention trials was tested prospectively at a single institution by evaluating sample adequacy and patient tolerability [46]. In this study, 86 high-risk women (median age of 54.5 years, 75 % postmenopausal) participated in two prospective phase II chemoprevention trials in which both DL and RPFNA were done at baseline. Only 31 % of subjects yielded adequate DL samples for evaluable analysis versus 96 % for RPFNA, concluding that DL is far less practical as a biomarker in chemoprevention trials, as compared with RPFNA. This study also demonstrated that both procedures were highly tolerable, without the development of hematoma, infection, or postprocedure pain requiring analgesic administration [46]. Similar findings were shown in Zalles et al., with 62 % and 96 % of high-risk women having a successful procedure with evaluable cytology in DL and RPFNA, respectively [16]. Both studies demonstrated that RPFNA was more likely to yield evaluable samples, but each method offered similar cytology results when adequate samples were provided [16, 46].

Evaluation of the cost effectiveness with RPFNA and DL in stratifying women for breast cancer preventive interventions was studied in 2004 and demonstrated effective means to motivate women at high risk for breast cancer to take tamoxifen if atypia were found. In this study, RPFNA was found to be both less expensive and more likely to produce an evaluable specimen, when compared with DL [47]. Furthermore, attempted DL has been dependent on the successful production of NAF for multiple studies, but when compared with concordant RPFNA specimens, atypical cells were observed in women with no NAF or an acellular lavage specimen [48]. Therefore, the lack of production of NAF does not exclude cytological atypia, and another means of screening for breast cancer is necessary.

**Conclusions**

Currently, we lack agents to prevent estrogen receptor-negative (ER−) breast cancer. A wealth of targeted inhibitors are undergoing clinical testing for the treatment of ER− breast cancer. However, in order to effectively test targeted agents for prevention, we first need biomarkers to identify women who have the highest likelihood of response. Strategies to rapidly test for response and resistance are also needed.

The past 20 years have focused on developing single biomarkers. However, it is clear that normal mammary gland homeostasis requires the coordinated regulation of phospho-protein signaling networks (rather than single proteins). Currently, we lack an understanding of the biology of breast cancer initiation. The combination of RPFNA or DL with high-throughput proteomic profiling holds promise for investigating whether dysregulation of interconnected signaling networks predicts cancer initiation and progression. This approach may also allow for rapid tracking of response to complex risk reduction interventions.

Low-toxicity targeted agents are potentially useful in the prevention of ER− breast cancer. However, emerging evidence suggests that some targeted agents, due to their specificity, may have unanticipated mechanisms of resistance [49]. Recently, it was shown that women receiving lapatinib for invasive breast cancer developed resistance via paradoxical activation of quiescent signaling pathways. Suppression of ErbB2-signaling by lapatinib in ER− breast cancer resulted in activation of FOXO3a and caveolin-1, leading to activation of ER-signaling [50]. This result was unexpected and highlights the importance of directly testing for protein signaling in mammary cytology, rather than relying on indirect markers of response, during administration of targeted agents. The combination of RPM with RPFNA or DL in multiple biomarker development and validation may not only serve to explain the underlying pathology of breast cancer.
cancer subtypes, but also directly test whether risk reduction strategies benefit individual women.

Disclosure  No potential conflicts of interest relevant to this article were reported.

Open Access  This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

Papers of particular interest, published recently, have been highlighted as:
• Of importance

1. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowl Project P-1 Study. J Natl Cancer Inst. 1998;90:1371–88.

2. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA. 2006;295:2727–41.

3. Hartmann LC, Schairer C, Wolfe J, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999;340:7784.

4. Rebbeck TR, Levin AM, Eisen A, et al. Breast cancer risk after prophylactic mastectomy in women with a family history of breast cancer. J Natl Cancer Inst. 1999;91:1475–9.

5. Kellogg GJ, Boone CW, Crowell JA, et al. Risk biomarkers and current strategies in chemopreventive drug development. J Cell Biochem Suppl. 1996;25:1–14.

6. Fabian CJ, Kimler BF, Zalles CM, et al. Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. J Natl Cancer Inst. 2000;92:1217–27.

7. Byrne C, Schairer C, Wolfe J, et al. Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst. 1995;87:1622–9.

8. Jernstrom HC, Olsson H, Borg A. Reduced testosterone, 17 beta-estradiol and sexual hormone binding globulin, and increased insulin-like growth factor-I concentrations, in healthy nulligravid women aged 19–25 years who were first and/or second degree relatives to breast cancer patients. Eur J Cancer Prev. 1997;6:330–40.

9. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 1998;351:1393–6.

10. Alfred DC, Hilsenbeck SG. Biomarkers in benign breast tissue disease: risk factors for breast cancer [editorial]. J Natl Cancer Inst. 1998;90:1247–8.

11. Marshall LM, Hunter DJ, Connolly JL, et al. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev. 1997;6:297–301.

12. Mansoor S, Ip C, Stamper C. Yield of terminal ductal lobule units (TLDU) in normal breast stereotactic core biopsy specimens: implications of biomarker studies. Breast J. 2000;6:220–9.

13. Sauter ER, Ross E, Daly M, et al. Nipple aspirate fluid: a promising non-invasive method to identify cellular markers of breast cancer risk. Br J Cancer. 1997;76:494–501.

14. Fabian CJ, Kimler BF, Brady DA, et al. A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers. Clin Cancer Res. 2002;8:3105–17.

15. Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet. 1998;62:145–58.

16. Zalles CM, Kimler BF, Kamel S, et al. Cytology patterns in random aspirates from women at high and low risk for breast cancer. Breast J. 1995;1:343–9.

17. Masood S, Frykberg ER, McLellan GL, et al. Prospective evaluation of radiologically directed fine-needle aspiration biopsy of nonpalpable breast lesions. Cancer. 1990;66:1480–7.

18. Deng GR, Lu Y, Zlotnikov G, et al. Loss of heterozygosity in normal tissue adjacent to breast carcinoma. Science. 1996;274:2057–9.

19. Bean GR, Scott V, Yee L, et al. Retinoic acid receptor-beta2 promoter methylation in random periareolar fine needle aspiration. Cancer Epidemiol Biomarkers Prev. 2005;14:790–8.

20. Bean GR, Kimler BF, Seewaldt VL. Long-term raloxifene in a woman at high risk for breast cancer. N Engl J Med. 2006;355:1620–2.

21. Bean GR, Ibarra-Drendall C, Goldenberg VK, et al. Hypermethylation of the breast cancer-associated gene 1 promoter does not predict cytologic atypia or correlate with surrogate end points of breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2007;16:50–6.

22. • Ibarra-Drendall C, Wilke LG, Zalles C, et al. Reproducibility of random periareolar fine needle aspiration in a multi-institutional Cancer and Leukemia Group B (CALGB) cross-sectional study. Cancer Epidemiol Biomarkers Prev. 2009;18:1379–85. This 5-institutional study demonstrates for the first time that the surrogate endpoints Masood cytology index score and cell count in the duplicate RPFNA samples from the same breast of each high-risk woman are highly reproducible (Spearman correlation coefficients of .831 and .726, respectively).

23. Khan SA, Masood S, Miller L, et al. Random fine needle aspiration of the breast of women at increased breast cancer risk and standard risk controls. Breast J. 1998;4:420–5.

24. Fabian CJ, Kamel S, Zalles C, et al. Identification of a chemoprevention cohort from a population of women at high risk for breast cancer. J Cell Biochem Suppl. 1996;25:112–22.

25. Khan QJ, Kimler BF, O’Dea AP, et al. Mammographic density does not correlate with Ki-67 expression or cytomorphology in benign breast cells obtained by random periareolar fine needle aspiration from women at high risk for breast cancer. Breast Cancer Res. 2007;9:R35.

26. Goldenberg V, Seewaldt VL, Scott V, et al. Atypia in random periareolar fine needle aspiration affects the decision of high-risk women to take tamoxifen for breast cancer chemoprevention. Cancer Epidemiol Biomarkers Prev. 2007;16:1032–43.

27. Seewaldt VL, Goldenberg V, Jones L, et al. Overweight and obese perimenopausal and postmenopausal women exhibit increased abnormal mammary epithelial cytology. Cancer Epidemiol Biomarkers Prev. 2007;16:613–6.

28. Bean GR, Bryson AD, Pilie PG, et al. Morphologically normal appearing mammary epithelial cells obtained from high-risk women exhibit methylation silencing of INK4a/ARF. Clin Cancer Res. 2007;13:6834–41.

29. Baker JC, Ostrander JH, Lem S, et al. ESR1 promoter hypermethylation does not predict atypia in random periareolar fine needle aspiration nor persistent atypia after 12 months tamoxifen chemoprevention. Cancer Epidemiol Biomarkers Prev. 2008;17:1884–90.

30. Evron E, Dooley WC, Umbricht CB, et al. Detection of breast cancer cells by methylation-specific PCR. Lancet. 2001;357:1335–6.

31. • Pilie PG, Ibarra-Drendall C, Troch MM, et al. Protein microarray analysis of mammary epithelial cells from obese and nonobese...
women at high risk for breast cancer: feasibility data. Cancer Epidemiol Biomarkers Prev. 2011;20:476–82. This pilot proteomic study demonstrates the potential of identifying differentially expressed proteins from limiting microdissected epithelial cells of nonobese and obese high-risk women. Preliminary data from such study suggest that early expression changes in the structural component of fat—namely, vimentin—may serve as a potential marker of risk and progression to breast cancer.

32. Ibarra-Drendall C, Troch MM, Barry WT, et al. Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways. Breast Cancer Res Treat. 2011 Jun 7. [Epub ahead of print]. This exploratory study shows that the interlinked components of mitochondrial apoptosis pathway are highly expressed in all mammary epithelial cells of high-risk women, but the delicate balance between proapoptotic and nonapoptotic proteins may tip the balance to cell survival during the early steps of mammary carcinogenesis.

33. Dooley WC, Ljung BM, Veronesi U, et al. Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst. 2001;93:1624–32.

34. Khan SA, Wiley EL, Rodriguez N, et al. Ductal lavage findings in women with known breast cancer undergoing mastectomy. J Natl Cancer Inst. 2004;96:1510–7.

35. Hartman AF, Daniel BL, Kurian AW, et al. Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma. Cancer. 2004;100:479–89.

36. Maddux AJ, Ashfaq R, Naftalis E, et al. Patient and duct selection for nipple duct lavage. Am J Surg. 2004;188:390–4.

37. Wood ME, Stanley MA, Crocker AM, et al. Ductal lavage of cancerous and unaffected breasts: procedure success rate and cancer detection. Acta Cytol. 2005;59:410–5.

38. Johnson-Maddux A, Ashfaq R, Cler L, et al. Reproducibility of cytologic atypia in repeat nipple duct lavage. Cancer. 2005;103:1129–36.

39. Visvanathan K, Santor D, Ali SZ, et al. The reliability of nipple aspirate and ductal lavage in women at increased risk for breast cancer—a potential tool for breast cancer risk assessment and biomarker evaluation. Cancer Epidemiol Biomarkers Prev. 2007;16:950–5.

40. Patil DB, Lankes HA, Nayar R, et al. Reproducibility of ductal lavage cytology and cellularity over a 6 month interval in high risk women. Breast Cancer Res Treat. 2008;112:327–33.

41. Loud JT, Beckjord EB, Nichols K, et al. Tolerability of breast ductal lavage in women from families at high genetic risk of breast cancer. BMC Womens Health. 2009;9(1):20.

42. King BL, Tsai SC, Gryga ME, et al. Detection of chromosomal instability in paired breast surgery and ductal lavage specimens by interphase fluorescence in situ hybridization. Clin Cancer Res. 2003;9:1509–16.

43. Fackler MJ, Malone K, Zhang Z, et al. Quantitative multiple methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid. Clin Cancer Res. 2006;12:3306–10.

44. Bhandare D, Nayar R, Bryk M, et al. Endocrine biomarkers in ductal lavage samples from women at high risk for breast cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:2620–7.

45. Khan SA, Lankes HA, Patil DB, et al. Ductal lavage is an inefficient method of biomarker measurement in high-risk women. Cancer Prev Res. 2009;2:265–73.

46. Arun B, Valero V, Logan C, et al. Comparison of ductal lavage and random periareolar fine needle aspiration as tissue acquisition methods in early breast cancer prevention trials. Clin Cancer Res. 2007;13:4943–8.

47. Ozanne EM, Esserman LJ. Evaluation of breast cancer risk assessment techniques: a cost-effectiveness analysis. Cancer Epidemiol Biomarkers Prev. 2004;13:2043.

48. Sharma P, Klemp JR, Simensen M, et al. Failure of high risk women to produce nipple aspirate fluid does not exclude detection of cytologic atypia in random periareolar fine needle aspiration specimens. Breast Cancer Res Treat. 2004;87:59.

49. Xia W, Bacus S, Hedge P, et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci USA. 2006;103:7795–800.

50. Chen FL, Xia W, Spector NL. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors. Clin Cancer Res. 2008;14:6730–4.